Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View


Shares of InMed Pharmaceuticals Inc. (INM) are gaining over 5% on Thursday morning after the clinical-stage company developing cannabinoid-based pharmaceutical drug candidates announced that its continued optimization of IntegraSyn has increased the cannabinoid yield to a level of 5 g/L.


RTTNews | Jun 17, 2021 11:18AM EDT

11:18 Thursday, June 17, 2021 (RTTNews.com) - Shares of InMed Pharmaceuticals Inc. (INM) are gaining over 5% on Thursday morning after the clinical-stage company developing cannabinoid-based pharmaceutical drug candidates announced that its continued optimization of IntegraSyn has increased the cannabinoid yield to a level of 5 g/L.

INM is currently trading at $2.95, up $0.15 or 5.3571%, on the Nasdaq. The stock has traded between $2.55 and $8.94 in the 52-week period.

InMed's cannabinoid yield of 5 g/L significantly exceeds currently reported industry yields, the company said. InMed continued to make important steps to further optimize the IntegraSyn manufacturing process, resulting in the improved yield of 5 g/L, surpassing InMed's previously reported yield levels of 2 g/L, an already commercially viable yield.

InMed said it is now focused on manufacturing scale-up to larger batch sizes in the second half of calendar year 2021.

Read the original article on RTTNews ( https://www.rttnews.com/3203263/stock-alert-inmed-pharma-gains-5.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC